Alzheimer’s disease remains one of medicine’s most intractable challenges. While existing therapies may address individual features of the disease, such as amyloid or tau, they have yet to reverse the progressive cognitive decline, inflammation, and neurodegeneration that characterize it. Evinco Therapeutics is developing nanoscale, natural killer cell-derived particles that carry proteins and microRNAs to target the neuroinflammation underlying Alzheimer’s. Alan Trounson, founder and CEO of Evinco Therapeutics, discusses the company’s multifaceted therapeutic approach, how these particles are designed to cross the blood-brain barrier, and their potential to modulate neuroinflammation, support the brain’s immune cells, and promote amyloid clearance.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from The Bio Report
Targeting Visceral Fat with RNA Therapeutics
Engineering T-Cell Engagers for Solid Cancers
Resetting Severe Allergies at Their Cellular Source
Innovating ADCs with Dual Targeting and Smarter Delivery
Get summaries like this every morning.
Free AI-powered recaps of The Bio Report and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.